Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL11207159 | 0.98 | THRB (0.44) | THRBVCAM1KCNN4DGAT1ALDH1A1 | |
| SCHEMBL29186298 | 0.95 | THRB (0.52) | THRBVCAM1KCNN4DGAT1ALDH1A1 | |
| SCHEMBL29186295 | 0.93 | THRB (0.56) | THRBVCAM1KCNN4DGAT1ALDH1A1 | |
| Fluoride SCHEMBL11206733 | 0.91 | THRB (0.54) | THRBVCAM1KCNN4DGAT1ALDH1A1 | |
| SCHEMBL517272 | 0.90 | DGAT1 (0.39) | THRBKCNN4DGAT1ALDH1A1MAPT | |
| SCHEMBL22767945 | 0.85 | ALDH1A1 (0.39) | THRBKCNN4DGAT1ALDH1A1ACLY | |
| SCHEMBL497763 | 0.85 | DGAT1 (0.39) | THRBKCNN4DGAT1ALDH1A1MAPT | |
| SCHEMBL11205420 | 0.82 | THRB (0.40) | THRBKCNN4DGAT1ALDH1A1SRC | |
| SCHEMBL3082673 | 0.82 | THRB (0.40) | THRBKCNN4DGAT1ALDH1A1SRC | |
| SCHEMBL672362 | 0.82 | THRB (0.40) | THRBKCNN4DGAT1ALDH1A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843865-B | Amorphous fluororesin, preparation method and application thereof, light-transmitting oxygen-permeable release film, and preparation method and application thereof | 宁波嘉玛材料科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-117843865-A | Amorphous fluororesin, preparation method and application thereof, light-transmitting oxygen-permeable release film, and preparation method and application thereof | 宁波嘉玛材料科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20170285469-A1 | RESIST COMPOSITION AND METHOD FOR FORMING RESIST PATTERN | TOKYO OHKA KOGYO, CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-9671693-B2 | Resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| EP-0327070-B1 | FLUOROCARBON CHAIN-CONTAINING ANTIGENIC CONJUGATES | BIOMIRA, INC. (CA) | 1993-05-05 | — | — | EP | disclosed |
| US-5055562-A | Haptens linked to protein carriers | BIOMIRA, INC. (CA) | 1991-10-08 | — | — | US | disclosed |
| EP-0327070-A1 | Fluorocarbon chain-containing antigenic conjugates | BIOMIRA, INC. (CA) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | CACNA1F, SLC6A5, IDUA | THRB 4466/4885VCAM1 3719/4885KCNN4 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.